DrugPatentWatch Database Preview

Details for Patent: 6,938,796

« Back to Dashboard

Which drugs does patent 6,938,796 protect, and when does it expire?

Patent 6,938,796 protects ADVAIR HFA, FLOVENT HFA, and VENTOLIN HFA, and is included in three NDAs.

Protection for ADVAIR HFA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighteen patent family members in seven countries.

Summary for Patent: 6,938,796

Title:	Indicating device
Abstract:	A device for dispensing metered dosages of a substance from a container includes a dispenser housing and an indicating device. The indicating device includes an indicator housing, at least one engagement member disposed in the indicator housing, a plurality of indicator members coaxially mounted in the indicator housing, and an actuator coupled to and moveable with the container relative to the plurality of indicator members and the dispenser housing. The actuator member is selectively engaged with at least one of indicator members and is operative to advance the at least one indicator member an incremental amount. The at least one engagement member is selectively engaged with an advancement member so as to bias the advancement member into operable engagement with at least one of the indicator members and move the at least one indicator member an incremental amount. A method for dispensing metered dosages of the substance is also provided.
Inventor(s):	Blacker; Richard (London, CA), Engelbreth; Daniel K. (London, CA), Schmidt; James N. (London, CA)
Assignee:	1263152 Ontario Inc. (London, CA)
Application Number:	10/369,091
Patent Claim Types: see list of patent claims	Device; Use;

Drugs Protected by US Patent 6,938,796

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-001	Jun 8, 2006		RX	Yes	Yes					Y
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-002	Jun 8, 2006		RX	Yes	Yes					Y
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006		RX	Yes	Yes					Y
Glaxo Grp Ltd	FLOVENT HFA	fluticasone propionate	AEROSOL, METERED;INHALATION	021433-003	May 14, 2004		RX	Yes	Yes					Y

Non-Orange Book US Patents Family Members for Patent 6,938,796

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,984,826	Indicating device
7,143,908	Indicating device
6,435,372	Delivery system for a medicament and method for the assembly thereof
6,561,384	Medicament dispensing device and method for the use thereof

International Patents Family Members for US Patent 6,938,796

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	1777499
Australia	753568
Canada	2315777
Canada	2604067